Home / Healthcare / Alpha Thalassemia Treatment Market By Type Of Drugs (Folic Acid, Deferasirox, Deferiprone, Hydroxyurea) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Alpha Thalassemia Treatment Market By Type Of Drugs (Folic Acid, Deferasirox, Deferiprone, Hydroxyurea) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Published: Jun 2019 | Published By: Acute Market Reports

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global ATT Market Portraiture
2.2. Global ATT Market, by Type of Drug, 2018 (US$ Mn)
2.3. Global ATT Market, by Geography, 2018 Vs 2027 (Value %)

Chapter 3. Global Alpha Thalassemia Treatment (ATT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Alpha Thalassemia Treatment (ATT) Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Folic Acid
4.3. Deferasirox
4.4. Deferiprone
4.5. Hydroxyurea

Chapter 5. Global Alpha Thalassemia Treatment (ATT) Market, Pipeline Analysis
5.1. Overview
5.2. Darbepoetin Alfa (Phase III)
5.3. Enriched Hematopoetic Stem Cell Infusion (Phase II)
5.4. In utero hematopoietic stem cell transplantation (Phase I)

Chapter 6. Global Alpha Thalassemia Treatment (ATT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America ATT Market Analysis, 2017 – 2027
6.2.1. North America ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.2.2. North America ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe ATT Market Analysis, 2017 – 2027
6.3.1. Europe ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.3.2. Europe ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific ATT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America ATT Market Analysis, 2017 – 2027
6.5.1. Latin America ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.5.2. Latin America ATT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) ATT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa ATT Market, by Type of Drugs, 2017–2027 (US$ Mn)
6.6.2. MEA ATT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. GlaxoSmithKline Plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Bellicum Pharmaceuticals
7.3. Novartis AG
7.4. Acceleron Pharma
7.5. Johnson & Johnson
7.6. Merck & Co Inc.
7.7. Alnylam Pharmaceuticals Inc.
7.8. Calimmune Inc.
7.9. Editas Medicine Inc.
7.10. Gilead Sciences Inc.

* Here we are using ATT as a short form of Alpha Thalassemia Treatment

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +